Please login to the form below

Not currently logged in
Email:
Password:

John Thievon named president of Dey Pharma

Former CEO of MiddleBrook Pharmaceuticals to help lead Mylan's integrated speciality pharmaceutical division

Mylan has named John Thievon as president of its integrated speciality pharmaceutical business Dey Pharma.

Thievon joins from MiddleBrook Pharmaceuticals where he was president and CEO.

He has more than 20 years experience in the healthcare industry and while serving as Middlebrook's CEO he oversaw the US pharma company's expansion from 18 employees to 450 and subsequent takeover by Victory Pharma.

He also worked as executive vice president of commercial operations for Adams Respiratory Therapeutics and spent four years at IMS Health.

Mylan's president Heather Bresch said: “Dey has been, and continues to be, a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

As president of Dey Pharma, Thievon will drive the company's focus on medicines to treat respiratory diseases, severe allergic reactions and psychiatric disorders.

21st December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....